Erythema multiforme

Human medicines European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna), COVID-19 mRNA vaccine,elasomeran,elasomeran / imelasomeran,elasomeran / davesomeran,andusomeran, Date of authorisation: 06/01/2021, Revision: 41[...]

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna), COVID-19 mRNA vaccine,elasomeran,elasomeran / imelasomeran,elasomeran / davesomeran,andusomeran, Date of authorisation: 06/01/2021, Revision: 41, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna), COVID-19 mRNA vaccine,elasomeran,elasomeran / imelasomeran,elasomeran / davesomeran,andusomeran, Date of authorisation: 06/01/2021, Revision: 41, Status: Authorised

Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) and Ocean Biomedical, Inc. Announce $75 Million Common Stock Purchase Transaction with White Lion Capital

Retrieved on: 
Thursday, September 8, 2022

NEW YORK and PROVIDENCE, R.I., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) (“Aesther” or the “Company”), a special purpose acquisition company (SPAC) has entered into an Agreement and Plan of Merger with Ocean Biomedical, Inc. (“Ocean”), a next-generation biopharma company. The combined company will work to accelerate the development of Ocean Biomedical’s core assets in oncology, fibrosis, and infectious diseases, all based on new target discoveries enabling first-in-class drug and vaccine candidates – developed through past and ongoing grants totaling $123.9 million.

Key Points: 
  • Aesther today announced that it has entered into a Common Stock Purchase Agreement (the "Purchase Agreement") with White Lion Capital LLC, a Nevada limited liability company (the "White Lion Capital").
  • White Lion Capital has no right to require any sales by the Company, but is obligated to make purchases from the Company as the Company directs in accordance with the Purchase Agreement.
  • About Aesther Healthcare Acquisition Corp.
    Aesther is a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
  • Neither of Ocean Biomedical or Aesther gives any assurance that Ocean Biomedical or Aesther, or the combined company, will achieve its expectations.

U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Pandemic Influenza Preparedness

Retrieved on: 
Thursday, August 25, 2022

The RAPIVAB purchase by the HHS Administration for Strategic Preparedness and Response will strengthen the nations preparedness to respond to a potential pandemic influenza event.

Key Points: 
  • The RAPIVAB purchase by the HHS Administration for Strategic Preparedness and Response will strengthen the nations preparedness to respond to a potential pandemic influenza event.
  • Efficacy of RAPIVAB is based on clinical trials of naturally occurring influenza in which the predominant influenza infections were influenza A virus and a limited number of patients infected with influenza B virus.
  • RAPIVAB is indicated for the treatment of acute uncomplicated influenza in patients 6 months and older who have been symptomatic for no more than 2 days.
  • Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use RAPIVAB.

Mitsubishi Tanabe Pharma America Announces Long-Term Findings from Post-Marketing Safety Study of RADICAVA® (edaravone)

Retrieved on: 
Wednesday, June 29, 2022

JERSEY CITY, N.J., June 29, 2022 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced findings from an analysis of post-marketing safety data evaluating RADICAVA® (edaravone) in a real-world setting during the first three years of availability in the United States (U.S.) for the treatment of amyotrophic lateral sclerosis (ALS). RADICAVA maintained a similar safety profile as seen in clinical trials, with no new safety signals or inconsistencies with the clinical trials identified over the treatment period. Study findings were published in a paper entitled, "Analysis of the U.S. Safety Data for Edaravone (Radicava®) From the Third Year After Launch," in Drugs in R&D.

Key Points: 
  • The U.S. Food and Drug Administration (FDA) approved RADICAVA (edaravone) on May 5, 2017 as a treatment for amyotrophic lateral sclerosis (ALS).2 Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) and Mitsubishi Tanabe Pharma Development America, Inc. (MTDA), commercialized in the U.S. by Mitsubishi Tanabe Pharma America, Inc.
  • About Mitsubishi Tanabe Pharma America, Inc.
    Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation's (MTPC) 100 percent owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc.
  • The U.S. headquarters of Mitsubishi Tanabe Pharma Development America, Inc. (MTDA) is located in Jersey City, New Jersey.
  • MTDA is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation's 100 percent-owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc. For more information, please visit https://mt-pharma-development-america.com/ .

Mitsubishi Tanabe Pharma America Presents 48-Week Results from Global Phase 3 Safety Clinical Study of RADICAVA ORS® (edaravone), an Oral Treatment for ALS

Retrieved on: 
Wednesday, June 1, 2022

JERSEY CITY, N.J., June 1, 2022 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced 48-week results from the global Phase 3 open-label, multi-center clinical trial (MT-1186-A01) assessing the safety and tolerability of RADICAVA ORS® (edaravone) in patients with amyotrophic lateral sclerosis (ALS). Details about the findings will be presented at the European Network to Cure ALS (ENCALS) Meeting 2022, being held in Edinburgh, Scotland, from June 1-3.

Key Points: 
  • "These data reinforce the potential significance of RADICAVA ORS and its important role in the treatment of this devastating disease."
  • Patients should not eat or drink (except water) within one hour after taking RADICAVA ORS.1
    Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) and Mitsubishi Tanabe Pharma Development America, Inc (MTDA), commercialized in the U.S. by Mitsubishi Tanabe Pharma America, Inc (MTPA).
  • About Mitsubishi Tanabe Pharma America, Inc.
    Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation's (MTPC) 100 percent owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc.
  • MTDA is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation's 100 percent-owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc. For more information, please visit https://mt-pharma-development-america.com/ .

2021 Global Dermatology Pipeline Database - by Indication, Clinical Trial Stages, Drug Mechanism Classes and Company - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 21, 2021

This report provides the most up-to-date information on key pipeline products in the global Dermatology market.

Key Points: 
  • This report provides the most up-to-date information on key pipeline products in the global Dermatology market.
  • It covers emerging therapies for Dermatology disorders in active clinical development stages including early and late-stage clinical trials.
  • The database provides Dermatology pipeline products by clinical trial stages including both early and late-stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
  • The database provides Dermatology pipeline products by their dominant drug mechanism class.

U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Delivery to Strategic National Stockpile

Retrieved on: 
Wednesday, September 1, 2021

We are pleased to provide additional doses of RAPIVAB to the SNS as we enter another influenza season of unpredictable severity, said Dr. William Sheridan, chief medical officer of BioCryst.

Key Points: 
  • We are pleased to provide additional doses of RAPIVAB to the SNS as we enter another influenza season of unpredictable severity, said Dr. William Sheridan, chief medical officer of BioCryst.
  • With the fulfillment of this new order, BioCryst will have delivered 40,000 doses under the contract.
  • Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use RAPIVAB.
  • Cases of anaphylaxis and serious skin/hypersensitivity reactions such as Stevens-Johnson syndrome and erythema multiforme have occurred with RAPIVAB.